Cargando…

Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial

BACKGROUND AND OBJECTIVE: Trastuzumab is a standard care as adjuvant chemotherapy (AdjCT) for patients with human epidermal growth factor receptor 2 (HER2)-positive primary breast cancer (BC) in Japan. However, no reports have evaluated its economics for patients with HER2-positive BC over 70 years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takumoto, Yuki, Shiroiwa, Takeru, Shimozuma, Kojiro, Iwata, Hiroji, Takahashi, Masato, Baba, Shinichi, Kobayashi, Kokoro, Hagiwara, Yasuhiro, Kawahara, Takuya, Uemura, Yukari, Mukai, Hirofumi, Taira, Naruto, Sawaki, Masataka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930935/ https://www.ncbi.nlm.nih.gov/pubmed/35233755 http://dx.doi.org/10.1007/s40261-022-01124-y

Ejemplares similares

Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017)

Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
por: Kawahara, Takuya, et al.
Publicado: (2022)

Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
por: Hagiwara, Yasuhiro, et al.
Publicado: (2020)

Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study
por: Sawaki, Masataka, et al.
Publicado: (2022)

Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L
por: Izumi, Shoki, et al.
Publicado: (2023)

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
por: Shiroiwa, Takeru, et al.
Publicado: (2017)

Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan
por: Mizota, Yuri, et al.
Publicado: (2017)

Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial
por: Shiroiwa, T, et al.
Publicado: (2011)

Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial
por: Narui, Kazutaka, et al.
Publicado: (2022)

Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials
por: Kawahara, Takuya, et al.
Publicado: (2022)

Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D
por: Shiroiwa, Takeru, et al.
Publicado: (2015)

Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
por: Shiroiwa, T., et al.
Publicado: (2016)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study
por: Watanabe, Toru, et al.
Publicado: (2017)

Psychometric properties of the Japanese version of the EQ-5D-Y by self-report and proxy-report: reliability and construct validity
por: Shiroiwa, T., et al.
Publicado: (2019)

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
por: Sawaki, Masataka, et al.
Publicado: (2023)

Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
por: Isogai, Ayaka, et al.
Publicado: (2023)

Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: Miyahara, Kana, et al.
Publicado: (2022)

Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A)
por: Iwatani, Tsuguo, et al.
Publicado: (2021)

Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group
por: Sawaki, Masataka, et al.
Publicado: (2018)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2021)

Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial
por: Kotani, Haruru, et al.
Publicado: (2021)

EQ-5D-Y Population Norms for Japanese Children and Adolescents
por: Shiroiwa, Takeru, et al.
Publicado: (2021)

Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer
por: Idota, Ai, et al.
Publicado: (2016)

The Benefits and Respective Side-Effects of PE Therapy for Intractable Kawasaki Disease
por: Mori, Masaaki, et al.
Publicado: (2021)

Realities in cost-effectiveness analyses: a study of castration-resistant prostate cancer patients using a medical claims database
por: Kunisawa, Susumu, et al.
Publicado: (2015)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer
por: SAWAKI, MASATAKA, et al.
Publicado: (2014)

The impact of smoking on male lower urinary tract symptoms (LUTS)
por: Kawahara, Takashi, et al.
Publicado: (2020)

Re: Geriatric 8 screening of frailty in patients with prostate cancer
por: Sugimura, Rumiko, et al.
Publicado: (2020)

A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy
por: Kikawa, Yuichiro, et al.
Publicado: (2022)

Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer
por: Yasui, Masato, et al.
Publicado: (2019)

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov
por: Sakamaki, Kentaro, et al.
Publicado: (2021)

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
por: Sawaki, Akira, et al.
Publicado: (2011)

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
por: Yamashiro, Hiroyasu, et al.
Publicado: (2018)

Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition
por: Inokuchi, Masafumi, et al.
Publicado: (2021)

The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition
por: Inokuchi, Masafumi, et al.
Publicado: (2019)

Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
por: Takatsuka, Daiki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0itl1985ak5cbjl45cmr8v6j0i